PSMA-targeting imaging agents
A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S 1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S 2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
1. A PSMA-specific imaging agent comprising a compound according to formula I:
wherein the agent is selected from the group consisting of E′E-Amc-Ahx-dEdEdEGYGGGC-NH 2 (SEQ ID NO: 7), E′E-Amc-Ahx-dEdEdEYK(Bn-NOTA)-NH 2 (SEQ ID NO: 8), and E′E-Ahx-EEEYK(Bn-NOTA)-NH 2 (SEQ ID NO: 9), and pharmaceutically acceptable salt thereof.
2. A method for imaging prostrate cancer in a tissue region of a subject comprising:
(a) administering to the subject a detectably effective amount of the PSMA-specific imaging agent of claim 1 ;
(b) allowing a sufficient amount of time for the PSMA-specific imaging agent to enter the tissue region; and
(c) performing imaging of the tissue region of the subject using an imaging device capable of detecting the imaging group.
3. The method of claim 2 , wherein the tissue region is the prostate gland.
4. The method of claim 2 , further comprising the step of conducting surgery to remove prostrate cancer from the subject.
5. The method of claim 4 , wherein the surgery is near-infrared fluorescence-guided robotic surgery.
6. The PSMA-specific imaging agent according to claim 1 , wherein the agent is E′E-Amc-Ahx-dEdEdEGYGGGC-NH 2 (SEQ ID NO: 7).
7. The PSMA-specific imaging agent according to claim 1 , wherein the agent is E′E-Amc-Ahx-dEdEdEYK(Bn-NOTA)-NH 2 (SEQ ID NO: 8).
8. The PSMA-specific imaging agent according to claim 1 , wherein the agent is E′E-Ahx-EEEYK(Bn-NOTA)-NH 2 (SEQ ID NO: 9).